FI
RARE icon

Fosun International’s Ultragenyx Pharmaceutical RARE Stock Holding History

Fosun International’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-54,144
Closed -$3.36M – 280
2019
Q2 		$3.36M Buy
54,144
+8,000
+17% +$509K 0.22% 68
2019
Q1 		$3.15M Buy
46,144
+21,144
+85% +$1.21M 0.2% 67
2018
Q4 		$1.05M Sell
25,000
-13,500
-35% -$738K 0.06% 130
2018
Q3 		$3.07M Buy
+38,500
New +$3.13M 0.15% 68

Other funds holding RARE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International's RARE Position: Q3 2019 in Review

Fosun International sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2019, closing a stake of 54,144 shares — an estimated $3.36M sold.

Fosun International first reported a position in RARE in Q3 2018 and held it in 4 quarters. The position peaked at $3.36M in Q2 2019. 172 funds tracked by Wall St. Rank hold RARE as of Q3 2019.

  • Fosun International reported no remaining Ultragenyx Pharmaceutical position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 54,144 Ultragenyx Pharmaceutical shares in Q3 2019, an estimated $3.36M.
  • Fosun International first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and held it in 4 quarters.
  • Fosun International's Ultragenyx Pharmaceutical position peaked at $3.36M in Q2 2019.
  • 172 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.